Tau Loop System
Tau’s special technology for trans-catheter treatment of both MR and TR with a single device in a single procedure
Venous blood is carried throughout the left atrium, from the left ventricle to the aorta and throughout the body. When the left ventricle contracts, arterial blood is supplied to the aorta, and the mitral valve must be closed to prevent reflux to the ventricle. Mitral valve insufficiency (MR) is a phenomenon in which the mitral valve is not completely closed due to external factors or aging.
When mitral valve insufficiency (MR) occurs, respiratory failure, arrhythmia, and heart failure occur, and in severe cases, death.
The number of patients with mitral regurgitation increases rapidly after age 55, and is four times the number of patients with aortic valves. The catheter-based mitral regurgitation (MR) treatment market is estimated to reach a CAGR of 10%, reaching $ 2.1 billion USD (2.5 trillion KRW) in 2024 (2018 basis).